# Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

> **NCT00006578** · NA · WITHDRAWN · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Ritonavir
- **DRUG:** Abacavir sulfate
- **DRUG:** Amprenavir
- **DRUG:** Lamivudine
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT00006578
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006578, "Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00006578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*